Today: 21 June 2026
DBS share price jumps toward 52-week high as broker upgrade meets Fed-rate nerves
27 January 2026
2 mins read

DBS share price jumps toward 52-week high as broker upgrade meets Fed-rate nerves

SINGAPORE, Jan 27, 2026, 14:47 SGT — Regular session

  • Shares of DBS Group climbed roughly 1.4%, reaching S$59.10 in afternoon trading, near the session peak.
  • UOB Kay Hian raised DBS to a “buy” rating, setting the target price at S$68.95. Phillip Securities, however, took a more cautious stance.
  • Investors are focused on the U.S. Fed’s decision set for Jan 28 and DBS’s full-year results due Feb 9.

Shares of DBS Group Holdings climbed 1.4% to S$59.10 in Tuesday afternoon trading, fluctuating between S$58.60 and S$59.35, edging closer to a new 52-week peak, according to Investing.com data.

This matters because bank investors are juggling two factors: the U.S. Federal Reserve’s guidance on interest rates due Wednesday, and DBS’s February report on margins and capital returns. The Fed wraps up its two-day meeting on Jan. 28.

UOB Kay Hian has raised its rating on DBS from “hold” to “buy,” setting a target price at S$68.95. Analysts John Cheong, Heidi Mo, and Tang Kai Jie said the stock’s yield still justifies its valuation despite recent gains. “Current yield suggests DBS is not expensive,” they noted in comments reported by The Business Times. The Business Times

Not everyone is on the same page. Phillip Securities downgraded DBS from “accumulate” to “neutral,” flagging the stock’s strong run and cautioning that falling local interest rates could squeeze net interest margins — the gap banks earn between loans and deposits — even as deposit costs shift, according to a sector note summary on SGinvestors.io. Still, the brokerage kept DBS as its sector pick, highlighting its capital return programme and fixed dividend per share. SG Investors

DBS dipped 0.6% to S$58.29 on Monday, dragged down alongside Singapore’s other major banks as the Straits Times Index fell, The Straits Times reported. Vishnu Varathan from Mizuho Securities noted investors are bracing for this week’s Fed decision, widely anticipating rates will hold steady.

Beyond Singapore, Asian equities have seen a pickup in risk appetite, driven by investors zeroing in on major U.S. earnings and central bank cues. This follows a volatile start marked by geopolitical tensions and tariff concerns.

In Singapore, the focus is on SORA — the Singapore Overnight Rate Average — a crucial benchmark for loan pricing and funding costs throughout the financial system. A decline in SORA typically pushes bank lending yields down, though how quickly deposits are repriced often determines if margins remain stable or shrink.

But the upside scenario carries a clear risk. Should markets begin to factor in faster rate cuts, or if local benchmarks drop faster than banks can lower deposit rates, net interest income could take a hit. That would put the dividend-and-buyback narrative under serious strain.

Investors in DBS will be keen to see if fee income and wealth management activities can counteract any margin pressure, and if credit costs remain under control amid slowing growth in certain regional areas. Guidance here could influence the stock more than the headline profit figure.

The next major event is the Fed decision on Jan. 28. After that, DBS will release its fourth-quarter and full-year 2025 results on Feb. 9, per the bank’s investor calendar.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Eli Lilly Shares Trade at 26.7% Discount Despite 45% Annual Gain, Valuation Analysis
    June 20, 2026, 9:19 PM EDT. Eli Lilly (LLY) stock closed recently at $1,098.57, up 45.1% over the past year but down 3% in the last week. The company, a major pharmaceutical player, shows a mixed valuation picture. A Discounted Cash Flow (DCF) model estimates intrinsic value at $1,497.84 per share, suggesting the stock is undervalued by 26.7%. The DCF method projects future free cash flows, discounting them to present terms to assess fair value. Despite a valuation score of 2 out of 6 from Simply Wall St, indicating some caution, the DCF analysis implies Eli Lilly's shares may be trading below their fundamental worth. Investors should weigh this alongside other valuation metrics and market factors before deciding.

Latest articles

Home Depot shares finish week up as investors weigh housing numbers

Home Depot shares finish week up as investors weigh housing numbers

21 June 2026
Home Depot jumped 2.1% to $334.28 in a shortened week as Wall Street rallied, but weak U.S. housing starts and upcoming May new-home-sales data keep pressure on the home-improvement outlook; the company reaffirmed 2026 sales and earnings targets despite volatile conditions and persistent housing affordability concerns.
Exxon Mobil stock dips after hours as Baytown freeze and carbon-capture launch set up earnings week
Previous Story

Exxon Mobil stock dips after hours as Baytown freeze and carbon-capture launch set up earnings week

Lloyds share price today: LLOY.L ticks higher as sanctions fine fades and results loom
Next Story

Lloyds share price today: LLOY.L ticks higher as sanctions fine fades and results loom

Go toTop